Sangamo BioSciences Inc. (SGMO) Receives $8.25 Consensus Target Price from Analysts
Sangamo BioSciences Inc. (NASDAQ:SGMO) has been given a consensus recommendation of “Buy” by the eight brokerages that are currently covering the stock. Four analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $8.25.
Several research analysts have issued reports on the company. Wedbush downgraded Sangamo BioSciences from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $30.00 to $4.00 in a report on Tuesday, November 1st. Zacks Investment Research raised Sangamo BioSciences from a “sell” rating to a “hold” rating in a report on Wednesday. Jefferies Group reaffirmed a “buy” rating on shares of Sangamo BioSciences in a report on Friday, August 5th. Piper Jaffray Cos. downgraded Sangamo BioSciences from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $9.00 to $5.00 in a report on Wednesday, October 19th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Sangamo BioSciences in a report on Wednesday, August 10th.
Hedge funds have recently added to or reduced their stakes in the stock. Emerald Acquisition Ltd. purchased a new stake in Sangamo BioSciences during the third quarter worth approximately $101,000. Quantitative Systematic Strategies LLC purchased a new stake in Sangamo BioSciences during the second quarter worth approximately $163,000. Princeton Alpha Management LP purchased a new stake in Sangamo BioSciences during the second quarter worth approximately $164,000. Janney Montgomery Scott LLC boosted its stake in Sangamo BioSciences by 88.5% in the second quarter. Janney Montgomery Scott LLC now owns 29,556 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 13,878 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in Sangamo BioSciences by 1.3% in the third quarter. HighTower Advisors LLC now owns 31,005 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 400 shares in the last quarter. Institutional investors and hedge funds own 62.24% of the company’s stock.
Shares of Sangamo BioSciences (NASDAQ:SGMO) opened at 3.20 on Monday. The firm’s market cap is $225.99 million. Sangamo BioSciences has a 12 month low of $3.10 and a 12 month high of $9.91. The stock has a 50 day moving average price of $3.84 and a 200 day moving average price of $5.04.
Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, October 26th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.02. Sangamo BioSciences had a negative return on equity of 45.02% and a negative net margin of 388.23%. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $4.24 million. During the same period in the prior year, the company posted ($0.13) EPS. The firm’s quarterly revenue was down 67.1% compared to the same quarter last year. On average, equities research analysts expect that Sangamo BioSciences will post ($1.14) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Sangamo BioSciences Inc. (SGMO) Receives $8.25 Consensus Target Price from Analysts” was published by Daily Political and is the propert of of Daily Political. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The original version of this article can be read at http://www.dailypolitical.com/2016/11/30/sangamo-biosciences-inc-sgmo-receives-8-25-consensus-target-price-from-analysts.html.
Sangamo BioSciences Company Profile
Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.
Receive News & Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.